Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique: survie globale et analyse de sous-groupes de l’étude ATHENA France-Reference-Cited by-同舟云学术

Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique: survie globale et analyse de sous-groupes de l’étude ATHENA France

Published:2014-09 Issue:9 Volume:101 Page:780-788
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:fr
Short-container-title:Bulletin du Cancer

Author:

Pierga Jean-Yves,Delva Rémy,Pivot Xavier,Espié Marc,Dalenc Florence,Serin Daniel,Veyret Corinne,Lortholary Alain,Gligorov Joseph,Joly Katelle,Hernandez Juana,Hardy-Bessard Anne-Claire

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference14 articles.

1. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

2. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer;Gray;J Clin Oncol,2009

3. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;J Clin Oncol,2010

4. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011

5. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment;Cell Proliferation;2016-06-16

2. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis;Breast Cancer Research and Treatment;2015-11-23

3. Coste del tratamiento del cáncer de mama por estadío clínico en el País Vasco;Revista Española de Salud Pública;2015-02